Insider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells $16,736,000.00 in Stock

Posted by Stanley Muller on Aug 28th, 2026

Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) insider Mark Goldsmith sold 80,000 shares of the business’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $209.20, for a total transaction of $16,736,000.00. Following the completion of the sale, the insider directly owned 267,330 shares of the company’s stock, valued at approximately $55,925,436. This trade represents a 23.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Revolution Medicines Stock Performance

Shares of NASDAQ:RVMD opened at $221.15 on Friday. The firm has a market cap of $47.40 billion, a PE ratio of -25.07 and a beta of 1.39. The firm’s 50 day simple moving average is $192.43 and its 200-day simple moving average is $148.17. Revolution Medicines, Inc. has a one year low of $37.56 and a one year high of $224.31. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same quarter in the previous year, the firm posted ($1.31) earnings per share. As a group, equities analysts predict that Revolution Medicines, Inc. will post -8.82 EPS for the current year.

Institutional Investors Weigh In On Revolution Medicines

A number of hedge funds and other institutional investors have recently bought and sold shares of RVMD. Vanguard Group Inc. grew its stake in Revolution Medicines by 6.7% during the 4th quarter. Vanguard Group Inc. now owns 16,719,886 shares of the company’s stock worth $1,331,739,000 after buying an additional 1,056,792 shares during the last quarter. State of Wyoming purchased a new stake in Revolution Medicines in the second quarter valued at about $1,769,000. Handelsbanken Fonder AB raised its stake in Revolution Medicines by 243.6% in the second quarter. Handelsbanken Fonder AB now owns 212,275 shares of the company’s stock valued at $39,755,000 after buying an additional 150,500 shares during the last quarter. Eagle Health Investments LP acquired a new stake in Revolution Medicines in the fourth quarter worth about $9,231,000. Finally, Assenagon Asset Management S.A. acquired a new stake in Revolution Medicines in the second quarter worth about $37,547,000. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Wall Street Analysts Forecast Growth

RVMD has been the topic of a number of recent research reports. Raymond James Financial reissued a “strong-buy” rating and set a $248.00 price target on shares of Revolution Medicines in a research report on Thursday. Oppenheimer upped their price objective on shares of Revolution Medicines from $230.00 to $260.00 and gave the stock an “outperform” rating in a research note on Thursday. Mizuho increased their target price on shares of Revolution Medicines from $185.00 to $215.00 and gave the stock an “outperform” rating in a report on Monday, July 6th. TD Cowen upgraded shares of Revolution Medicines to a “strong-buy” rating in a report on Monday. Finally, HC Wainwright raised their target price on shares of Revolution Medicines from $195.00 to $280.00 and gave the company a “buy” rating in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $193.28.

View Our Latest Research Report on Revolution Medicines

More Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

Positive Sentiment: Landmark FDA approval: RASONQUE is described as the first broad RAS-targeted medicine approved for metastatic pancreatic cancer, addressing a disease with limited treatment options and potentially validating Revolution Medicines’ RAS/MAPK drug-development platform. FDA approval announcement
Positive Sentiment: Commercial opportunity expands: Analysts said the RASONQUE label creates a sizable opportunity, while RBC viewed the company’s planned launch as rapid. Management’s discussion also emphasized the approval’s implications for broader RAS-driven cancer treatment and future indications. Rasonque label expansion analysis
Positive Sentiment: Higher analyst targets: Truist raised its price target from $231 to $239 and maintained a Buy rating, while Wedbush increased its target from $201 to $225 and kept an Outperform rating. These revisions reflect improved confidence following the approval. Analyst price target changes
Neutral Sentiment: Pricing and launch execution will matter: Revolution Medicines priced RASONQUE at approximately $39,800 per month. The price supports substantial revenue potential, but payer coverage, patient access and real-world adoption could influence how quickly the approval translates into sales. Rasonque pricing article
Negative Sentiment: Insider selling and ongoing losses remain risks: Insider Mark Goldsmith sold 80,000 shares for roughly $16.7 million, reducing his holdings by about 23%. Revolution Medicines also remains unprofitable, and its latest quarterly loss exceeded analyst expectations, so the stock’s valuation depends heavily on successful commercialization and pipeline progress. Insider sale report

About Revolution Medicines

(Get Free Report)

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.